Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Heart Failure, CongestiveRenal Insufficiency, Chronic
Interventions
DRUG

Erythropoietin administration

50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)

Trial Locations (2)

3800 BM

Meander Medical Center Amersfoort, Amersfoort

3508 GA

Univ. Medical Center Utrecht, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dutch Heart Foundation

OTHER

lead

UMC Utrecht

OTHER